Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Moderna, Inc.    MRNA

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : Severe allergic reactions to Moderna vaccine appear rare -CDC report

01/22/2021 | 02:21pm EST

Jan 22 (Reuters) - Severe allergic reactions to Moderna Inc's coronavirus vaccine appear to be quite rare, the U.S. Centers for Disease Control and Prevention (CDC) said on Friday, after over 4 million people had received their first dose.

Based on the data, the CDC said anaphylaxis, a life-threatening allergic reaction, occurred at a rate of 2.5 cases per 1 million shots administered.

The agency cautioned that the risk of anaphylaxis was difficult to compare to non–COVID-19 vaccines because it is still so early in the vaccination program.

As of Jan. 10, there were 10 cases of anaphylaxis reported among 4.04 million people who received their first doses of Moderna's two-shot vaccine, according to the agency's Morbidity and Mortality Weekly Report. (https://bit.ly/3973U4N)

The CDC said the characteristics of severe allergic reactions to Moderna's vaccine were similar to those reported with the COVID-19 vaccine from Pfizer Inc and partner BioNTech SE.

Earlier this month, the CDC reported severe allergic reactions to the Pfizer/BioNTech shot occurred at a rate of 11.1 per 1 million vaccinations.

For both vaccines, symptoms presented within minutes after vaccination and were more common among women. Many of those who suffered anaphylaxis after receiving either vaccine had a history of allergies or allergic reactions, and several had an anaphylaxis episode in the past, the CDC said.

The agency said locations administering COVID-19 vaccines should screen recipients, have necessary supplies and staff members to manage anaphylaxis, and immediately treat suspected cases with an epinephrine injection, the same drug in EpiPens. (Reporting by Vishwadha Chander in Bengaluru and Julie Steenhuysen in Chicago; Editing by Caroline Humer and Bill Berkrot)


© Reuters 2021
All news about MODERNA, INC.
01:33aASTRAZENECA : European Medicines Agency Releases Recommendations for COVID-19 Ja..
MT
02/25Health Care Down Amid Vaccine Breakthroughs -- Health Care Roundup
DJ
02/25Wall Street ends sharply lower, tech selloff weighs as bond yields climb
RE
02/25MODERNA : EU vows to speed vaccine roll out, presses drug makers
AQ
02/25SECTOR UPDATE : Health Care Stocks Fall Thursday but Mostly Resist Steep Slide
MT
02/25MODERNA : The latest developments on COVID-19 in Canada on Thursday, Feb. 25, 20..
AQ
02/25MODERNA : U.S. administers 68.3 mln doses of COVID-19 vaccines - CDC
RE
02/25EU drug regulator outlines plan to fast track variant-modified COVID vaccines
RE
02/25ASTRAZENECA : Under fire in EU, AstraZeneca CEO says 'hopefully' will meet vacci..
RE
02/25MODERNA : EU leaders seek to inject energy into slow vaccine rollout
AQ
More news
Financials (USD)
Sales 2020 502 M - -
Net income 2020 -582 M - -
Net cash 2020 2 597 M - -
P/E ratio 2020 -119x
Yield 2020 -
Capitalization 58 715 M 58 715 M -
EV / Sales 2020 112x
EV / Sales 2021 4,11x
Nbr of Employees 1 100
Free-Float 90,0%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 153,79 $
Last Close Price 148,38 $
Spread / Highest target 40,2%
Spread / Average Target 3,64%
Spread / Lowest Target -46,1%
EPS Revisions
Managers and Directors
NameTitle
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.42.03%58 715
LONZA GROUP AG4.15%48 455
IQVIA HOLDINGS INC.7.47%37 221
CELLTRION, INC.-14.21%34 686
SEAGEN INC.-14.30%28 084
HANGZHOU TIGERMED CONSULTING CO.,LTD-7.61%20 223